Crestor (Rosuvastatin) Cost in New York: 2026 Prices, Insurance, and Savings

What Rosuvastatin Actually Costs at New York Pharmacies in 2026

The sticker price for brand-name Crestor from AstraZeneca sits near $290 per month in 2026, but almost no one pays that. Generic rosuvastatin, which the FDA approved in 2016, averages roughly $15 per month across New York retail pharmacies. That price gap matters because rosuvastatin is one of the most prescribed statins in the country, and New York has more than 5,000 licensed retail pharmacy locations competing on generic pricing.

Prices vary by borough and region. Manhattan pharmacies in high-rent corridors may charge $18 to $22 for a 30-day generic supply, while pharmacies in Buffalo, Rochester, or Albany often price closer to $10 to $14. Large chains like CVS, Walgreens, and Rite Aid tend to cluster around $13 to $16 for the most common doses (10 mg and 20 mg tablets). Independent pharmacies sometimes beat chain pricing by $2 to $4, especially for cash-pay patients who ask directly.

Warehouse clubs represent another option. Costco pharmacies in New York (which do not require a membership for pharmacy services under state law) have listed 90-day supplies of rosuvastatin 10 mg for under $30 in several metro-area locations. The 40 mg strength costs slightly more, typically $18 to $22 for a 30-day fill. These prices shift quarterly, so verifying at the counter or through each pharmacy's online price checker remains the most reliable approach.

For patients on a fixed income or without insurance, the difference between $15 and $290 per month is the difference between adherence and abandonment. A 2019 analysis published in the Journal of the American Heart Association found that statin non-adherence increased cardiovascular event risk by 45% over a 3-year follow-up period [1]. Cost remains the single largest driver of non-adherence in statin therapy.

New York Medicaid Coverage for Rosuvastatin

New York Medicaid covers rosuvastatin, but the program requires prior authorization before dispensing. This means the prescribing clinician must submit documentation confirming the medical necessity of rosuvastatin specifically, rather than a lower-cost statin like atorvastatin or pravastatin.

The PA process in New York typically takes 24 to 72 hours through the state's eMedNY system. Prescribers submit the request electronically, and the state's pharmacy benefit manager reviews it against the preferred drug list. Rosuvastatin sits on the non-preferred tier for most Medicaid managed care plans in New York, which is why the PA requirement exists. Atorvastatin, by contrast, is preferred and does not require PA under most NY Medicaid managed care contracts.

Clinicians can justify rosuvastatin over atorvastatin in several scenarios: documented atorvastatin intolerance, failure to reach LDL targets on maximum atorvastatin dosing, or specific clinical indications where rosuvastatin has stronger trial evidence. The JUPITER trial (N=17,802) demonstrated that rosuvastatin 20 mg reduced major cardiovascular events by 44% in patients with elevated high-sensitivity C-reactive protein but normal LDL cholesterol [2]. This trial is frequently cited in PA submissions when the clinical rationale centers on inflammatory risk reduction rather than pure LDL lowering.

Once approved, the PA typically lasts 12 months before renewal. Medicaid patients pay $0 to $3 per fill depending on their managed care plan. Patients enrolled in Medicaid through the Essential Plan or a managed care organization should confirm rosuvastatin coverage through their specific plan's formulary, as coverage terms can vary between organizations like Fidelis, Healthfirst, MetroPlus, and Molina.

Insurance Coverage Beyond Medicaid

Most commercial insurance plans in New York cover generic rosuvastatin on Tier 1 or Tier 2 of their formularies, which translates to copays of $5 to $25 per month. Brand Crestor, when covered at all, typically falls on Tier 3 or the non-preferred brand tier, with copays ranging from $45 to $100 per month.

Plans sold on the New York State of Health marketplace (the state's ACA exchange) must cover at least one statin under the essential health benefits requirement. Most exchange plans include generic rosuvastatin. The specific tier placement varies by insurer. For 2026, major exchange carriers in New York include Empire BlueCross BlueShield, Oscar Health, Fidelis Care, and Healthfirst.

Employer-sponsored plans in New York follow similar patterns but with wider variation. Large self-insured employers often negotiate aggressive generic pricing through pharmacy benefit managers like Express Scripts, CVS Caremark, or OptumRx, pushing rosuvastatin copays as low as $0 to $10. Small-group plans may have higher cost-sharing.

Medicare Part D plans in New York almost universally cover generic rosuvastatin, and many place it on the $0 copay preferred generic tier. The 2025 Inflation Reduction Act provisions that capped Part D out-of-pocket spending at $2,000 per year continue to benefit Medicare enrollees who take multiple branded medications alongside rosuvastatin. For a patient whose rosuvastatin is their only prescription, the annual cost under most Part D plans falls between $0 and $120.

According to the American College of Cardiology's 2018 cholesterol management guideline, rosuvastatin 20 mg to 40 mg qualifies as high-intensity statin therapy, recommended for patients with clinical atherosclerotic cardiovascular disease, LDL above 190 mg/dL, or a 10-year ASCVD risk score of 7.5% or higher [3]. Insurance plans rarely deny coverage for patients meeting these guideline-defined indications.

Discount Programs and Savings Cards

Several pathways exist to reduce rosuvastatin costs below standard retail pricing in New York. The most accessible is GoodRx or similar discount aggregators, which compile negotiated cash prices across pharmacy networks. GoodRx pricing for rosuvastatin 10 mg in New York City typically ranges from $8 to $14 for a 30-day supply, depending on the pharmacy.

AstraZeneca's savings card program for brand-name Crestor offers eligible commercially insured patients copays as low as $3 per month. The card does not apply to government-insured patients (Medicare, Medicaid, TRICARE, VA). Patients must have commercial insurance that covers Crestor to use the card. Without insurance coverage, the savings card alone will not bring brand Crestor close to generic pricing.

Mark Cuban's Cost Plus Drugs (costplusdrugs.com) lists rosuvastatin at a transparent manufacturer cost plus a fixed 15% margin and $5 dispensing fee. Their 2026 pricing for rosuvastatin 20 mg sits near $4 to $6 for a 30-day supply, shipped to New York addresses. This option works well for uninsured patients or those with high-deductible plans who haven't met their deductible.

New York State also operates the Elderly Pharmaceutical Insurance Coverage (EPIC) program for residents age 65 and older who earn under $75,000 (single) or $100,000 (married). EPIC supplements Medicare Part D and can reduce copays on rosuvastatin to $3 to $20 per prescription, depending on the enrollee's income tier. The program is unique to New York and represents a meaningful benefit for older adults on fixed incomes.

Dr. Robert Rosenson, a lipidologist at Mount Sinai Hospital in New York, has stated: "The cost barrier for generic statins has largely disappeared, but patients still need to know where to look. A $15 generic statin that a patient doesn't fill is less effective than a $4 one that they do." This underscores the importance of price transparency in statin adherence.

Compounded Rosuvastatin in New York

Compounded rosuvastatin is available through licensed 503A compounding pharmacies in New York State. These pharmacies operate under the oversight of the New York State Board of Pharmacy and must comply with both state and federal compounding regulations established under Section 503A of the Federal Food, Drug, and Cosmetic Act.

Compounding fills a specific clinical niche. Patients who cannot swallow standard tablets, need a dye-free formulation, require a dose not commercially available (such as 3 mg or 7.5 mg), or have documented allergies to inactive ingredients in manufactured tablets may benefit from compounded rosuvastatin. The compounded product is prepared from bulk pharmaceutical-grade rosuvastatin calcium powder and can be formulated as a suspension, capsule, or flavored liquid.

Pricing for compounded rosuvastatin in New York varies widely by pharmacy and formulation. Some 503A pharmacies price compounded rosuvastatin suspensions between $25 and $60 for a 30-day supply. Others, particularly those operating through telehealth-affiliated models, may offer lower pricing when bundled with a consultation fee.

One critical distinction: compounded rosuvastatin is not FDA-approved and is not AB-rated to commercial products. Insurance plans, including Medicaid, rarely cover compounded medications. Patients should also verify that their compounding pharmacy holds a current New York State license and follows USP 795/800 standards for non-sterile compounding.

The FDA's guidance on compounding makes clear that 503A compounding is permitted only to fill patient-specific prescriptions, not for general distribution or "office stock." New York's Board of Pharmacy enforces this boundary and has issued violations to pharmacies that compound without valid prescriptions.

Telehealth Access to Rosuvastatin in New York

New York State permits prescribing rosuvastatin via telehealth. Since the pandemic-era regulatory expansions, New York has maintained broad telehealth prescribing authority for non-controlled substances, and rosuvastatin falls squarely in that category. A clinician licensed in New York can evaluate a patient via synchronous video or audio visit, review labs, and prescribe rosuvastatin electronically to any New York pharmacy.

Several telehealth platforms now offer statin management as part of cardiovascular risk reduction programs. HealthRX, Ro, Hims, and others provide online consultations where clinicians can order lipid panels through partner labs, review results, and prescribe appropriate statin therapy. This model is particularly useful for patients in rural parts of New York State (the Adirondacks, Southern Tier, North Country) where access to cardiologists or lipidologists is limited.

The American Heart Association's 2023 telehealth position statement supports remote management of chronic cardiovascular risk factors, including hyperlipidemia, when in-person visits are not feasible [4]. Lipid management lends itself well to telehealth because monitoring relies primarily on lab values rather than physical examination findings.

Telehealth prescribers in New York must still meet the same standard of care as in-person clinicians. That means reviewing a recent lipid panel (within 3 to 12 months), assessing liver function at baseline, discussing potential side effects including myopathy, and selecting a dose based on the patient's ASCVD risk profile.

How Rosuvastatin Compares to Other Statins on Cost

Rosuvastatin is not the cheapest generic statin, but the difference is small. Atorvastatin (generic Lipitor) averages $8 to $12 per month in New York. Simvastatin and pravastatin cost slightly less, around $4 to $8. Rosuvastatin at $15 per month is marginally more expensive but remains well within affordable range for most patients.

The clinical question is whether the extra few dollars buys meaningful benefit. The STELLAR trial (2003) directly compared statins across doses and found that rosuvastatin 10 mg reduced LDL cholesterol by 46%, compared to 37% for atorvastatin 10 mg [5]. At maximum doses, rosuvastatin 40 mg achieved a 55% LDL reduction versus 51% for atorvastatin 80 mg. These differences are modest but can matter clinically for patients near their LDL goal who need an extra 5% to 10% reduction without doubling their dose.

The 2018 ACC/AHA cholesterol guideline classifies both rosuvastatin 20 to 40 mg and atorvastatin 40 to 80 mg as high-intensity statin therapy [3]. For most patients, either drug at appropriate doses achieves guideline targets. The choice between them often comes down to tolerability, drug interactions, and, yes, cost.

Dr. Steven Nissen of the Cleveland Clinic has noted: "In an era where generic rosuvastatin costs a few dollars more than generic atorvastatin, the decision should be driven by clinical factors, not price. Both are extraordinary bargains compared to the cardiovascular events they prevent."

For patients on tight budgets who need high-intensity therapy, atorvastatin 40 mg at $8 per month may be the best value. For patients who tolerate rosuvastatin better or need the extra LDL-lowering potency at a given dose, the $15 price point remains accessible.

Filling Your Prescription: Practical Steps for New York Residents

Start by confirming your insurance formulary placement for rosuvastatin. Call the number on your insurance card or check the plan's online formulary tool. If rosuvastatin requires prior authorization, ask your prescriber to submit the PA before sending the prescription to the pharmacy.

Compare prices across at least three pharmacies. Use GoodRx, RxSaver, or call pharmacies directly. Prices can differ by $5 to $10 within a single zip code. If you are uninsured, ask pharmacies about their cash-pay generic pricing rather than the "retail" price, which is often inflated.

For Medicare Part D enrollees, check whether your plan's preferred pharmacy network offers $0 generic copays. Many Part D plans in New York designate Walmart, Costco, or certain chain pharmacies as preferred, with lower copays than non-preferred pharmacies.

If cost remains a barrier, consider Mark Cuban's Cost Plus Drugs for mail-order delivery, the EPIC program (if age 65+), or the NeedyMeds database for additional patient assistance programs. The baseline rosuvastatin dose for most patients is 10 mg or 20 mg once daily, taken at any time of day, with or without food.